FDA
-
-
-
-
-
-
-
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
-
-
-
-
-
-
-
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
-
-
-
-
-
-
-
Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
-
-
-
-
-
-
-
Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
-
-
-
-
-
-
-
Syndax Pharmaceuticals' (SNDX) SNDX-5613 Granted Orphan Drug Designation in Europe for Treatment of Acute Myeloid Leukemia
-
-
-
-
-
-
-
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
-
251,409 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All